Summit Therapeutics Inc. Common Stock
Here’s whether Summit Therapeutics Inc. Common Stock (SMMT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.59% over 10 days); 3-month momentum positive (+47.6%). Concerns: RSI 89 — overbought, elevated pullback risk. Currently 31.9% off its 52-week high. Score: +4/7.
SMMT is in a confirmed uptrend, trading above both its 50-day ($16.95) and 200-day ($19.83) moving averages. With an RSI of 89.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +9.1% compares to +35.1% for SPY (trailed the market by 26.0%). The current 31.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.